

Supplemental Table S1, List of antibodies.

Mouse anti- β -ACTIN	Sigma-Aldrich	Cat# A5316
Rabbit anti-NRF2	Abcam	Cat# Ab62352
Rabbit anti-NRF2	Santa Cruz Biotechnology	Cat# SC-13032x
Rabbit anti-GCLC	Abcam	Cat# Ab41463
Rabbit anti-NQO1	Abcam	Cat# Ab80588
Rabbit anti-HMOX1	Abcam	Cat# Ab68477
Rabbit anti-NQO1	Abcam	Cat# Ab80588
Rabbit anti-Catalase	Santa Cruz Biotechnology	Cat# SC-50508
Rabbit anti-GCLC	Abcam	Cat# Ab41463
Rabbit anti-GCLM	Abclonal	Cat# A5314
Rabbit anti-SLC7A11	Cell Signaling Technology	Cat# 12691
Rabbit anti-EZH2	Sigma-Aldrich	Cat# 07-689
Mouse anti-adult hemoglobin (HbA)	Santa Cruz Biotechnology	Cat# SC-21757
Mouse anti-fetal hemoglobin (HbF)	Santa Cruz Biotechnology	Cat# SC-21756
Sheep IgG isotype FITC control antibody	MyBioSource	Cat# MBS524511
FITC conjugated mouse anti-HbF	BD biosciences	Cat# 552829
Donkey anti-Mouse IgG, secondary, HRP	Santa Cruz Biotechnology	Cat# SC-2096
Donkey anti-Rabbit IgG, secondary, HRP	Santa Cruz Biotechnology	Cat# SC-2077

Supplemental Table S2, List of DNA oligoes.

cDNA analysis	Forward primer	Reverse primer
β -ACTB (both human NM_001101 and mouse NM_007393)	GACGAGGCCCGAGCAAGAGAGG	TCTCAAACATGATCTGGGTCATC
CAT (both human NM_001752 and mouse NM_009804)	GGTTTGGCCTCACAAGGACTACC	CGGTAGGGACAGTTCACAGGTAT
GCLC (both human NM_001498 and mouse NM_010295)	GAGTATGGGAGTTACATGAT	TCTGGAAAGAAGAGGGACTT
NQO1 (both human NM_000903 and mouse NM_008706)	ATCCTGGAAGGATGGAAGAAAC	TCTAGCTTTGATCTGGTTGTCAG
GCLM (both human NM_002061 and mouse NM_008129)	AAGTGCCCGTCCACGCACAG	CTTCTAGTTGATGATGAAGA
SLC7A11 (both human NM_014331 and mouse NM_011990)	CTCCAGAACACGGGCAGCGT	CAAATGCCAGGGATATCACA
KDM6a (human NM_001291415)	TCACTTCAACCTCTTATTGGAAG	CTTTGAACATAAGCCCAAGTCGT
KDM6b (human NM_001080424)	TCCTCCTGCCACCAAATACCTC	CCAGCCCATCAGGTAGGATCTTG

<i>EZH1</i> (human NM_001991)	TGTTCCCATCATGTATTCCTGG	GATCCAGGGATCATCTCTTCTTC
<i>EZH2</i> (human NM_004456)	ATGGGCCAGACTGGGAAGAAAT C	GCGCAATGAGCTCACAGAAGTCA
<i>HBG1</i> (human NM_000559)	GTGGATCCTGAGAACTTCA	GCTTGCAGAATAAAGCCTATCCTTG
<i>HBB</i> (human NM_000518)	GTGGATCCTGAGAACTTCA	TTAGGCAGAATCCAGATGCTCAAGG
<i>Tgfb</i> (mouse NM_011577)	GGTGCTCGCTTTGTACAACA	ACTGCTTCCCGAATGTCTGA
<i>Tgfa</i> (mouse NM_031199)	CATTGAGCCCACCCTTGTTT	ATGAGGAACAGGCAGCTTCT
<i>Il1b</i> (mouse NM_008361)	ACTCATTGTGGCTGTGGAGA	TGTTGTTTATCTCGGAGCCT
<i>Il6</i> (mouse NM_031168)	CTGGGGATGTCTGTAGCTCA	CAGGTCTGTTGGGAGTGGTA
<i>Ccl2</i> (mouse NM_011333)	AGGTGTCCCAAAGAAGCTGT	ACAGAAGTGCTTGAGGTGGT
<i>Ccl3</i> (mouse NM_011337)	GATCTGCGCTGACTCCAAAG	GTCCCTCGATGTGGCTACTT
<i>Ccl4</i> (mouse NM_013652)	CCTCTCTCTCCTTTGCTCG	CTCTCCTGAAGTGGCTCCTC
<i>Ccl5</i> (mouse NM_013653)	TGCCACGTCAAGGAGTATT	AGATGCCCATTTTCCAGGA
<i>Ccl7</i> (mouse NM_013654)	TGAAGCCAGCTCTCTCACTC	TATAGCCTCCTCGACCCACT
<i>Ccl11</i> (mouse NM_011330)	CACAAAGCACCTGGACCAAA	TCGTCCATTGTGTTCTCTCA
<i>Ccl17</i> (mouse NM_011332)	GCTTCTGGGGACTTTTCTGC	TTGAAACCATGGACAGCAGC
<i>Cxcl1</i> (mouse NM_008176)	AGTTCCAGCACTCCAGACTC	CTCGCGACCATTCTTGAGTG
<i>Cxcl10</i> (mouse NM_021274)	ACATCAGCTGCTACTCCTCC	CTGAGCTAGGGAGGACAAGG
ChIP analysis	Forward primer	Reverse primer
<i>HBG1</i> (human NM_000559)	CTGAAACGGTCCCTGGCTA	CTGTGAAATGACCCATGGCG
<i>HBB</i> (human NM_000518)	CACTTAGACCTCACCTGTGGAG CCACACCCTAGGGTTGGC	CTTGTAACCTTGATACCAACCTG
<i>HMOX1</i> ARE (human NM_002133)	CACGGTCCCGAGGTCTATT	AAGGGTGGAGGAGCTGCTAT
<i>NQO1</i> ARE (human NM_000903)	ATTACCTGCCTTGAGGAGCA	CAGAGGCCTCAAAAATCTGG
<i>SLC7A11</i> ARE (human NM_014331)	TGCATGAGGAAAATGATCCA	GCATGGAAAAGGTCAGAACC
<i>Nqo1</i> ARE (mouse NM_008706)	TTTCTAAGAGCAGAACGCAGCAC	AGACCTCCTGGGTACAAAATGGA
<i>Cat</i> ARE (mouse NM_009804)	GTAGGGAGAGACACGGTTTCCA	AGAAAAGACAAATCAAGAACCAG
<i>Hmox1</i> ARE (mouse NM_010442)	AGTCACGGTCCCGAGGTCT	TCGAGTTGATCTTCTTACAGTG

<i>Gclc</i> ARE (mouse NM_010295)	CTCTTAACCGCTGAGCCATC	TATTGGGAGATGGGGAGAGA
<i>Slc7a11</i> ARE (mouse NM_011990)	AAATTTCCGGCTTTGAGCTA	CTTGTCAGCACAGCGTGATT
shRNA constructs	Forward primer	Reverse primer
shControl	CCGGCCTAAGGTTAAGTCGCCCT CGCTCGAGCGAGGGCGACTTAA CCTTAGGTTTTTG	AATTCAAAAACCTAAGGTTAAGTCGC CCTCGCTCGAGCGAGGGCGACTTAA CCTTAGG
sh <i>EZH2</i> construct 1 (targeting human <i>EZH2</i> NM_004456)	CCGGTGACTTCTGTGAGCTCATT GCCTCGAGGCAATGAGCTCACA GAAGTCATTTTTG	AATTCAAAAATGACTTCTGTGAGCTC ATTGCCTCGAGGCAATGAGCTCACA GAAGTCA
sh <i>EZH2</i> construct 2 (targeting human <i>EZH2</i> NM_004456)	CCGGGTTTGTGGCGGAAGCGT GTACTCGAGTACACGCTTCCGCC AACAACTTTTTG	AATTCAAAAAGTTTGTGGCGGAAGC GTGTACTCGAGTACACGCTTCCGCC AACAAAC

Supplemental Figures




Figure S1, Effect of HbF inducers on cellular proliferation and viability of SCD erythroblasts. Cellular proliferation (A) and viability (B) of SCD erythroblasts at day 12 after 48 h of treatments with 0.1% DMSO, 50 μ M hydroxyurea (HU), 100 μ M dimethyl fumarate (DMF), 2.5-20 μ M simvastatin (SIM), or untreated control (UT). Data represents mean \pm SD of three biological replicates. *, $p < 0.05$.




Figure S2, Hematological indices of SCD mice treated with simvastatin. Complete blood count and differentials for peripheral blood of the SCD mice, at week 0, week 2, and week 4 of treatment of simvastatin (SIM, 7.5-15 mg/kg), hydroxyurea (HU, 50 mg/kg) or dimethyl fumarate (DMF, 50 mg/kg) daily, 5 days a week. One-way ANOVA with Bonferroni's multiple comparison test was used for statistical analysis (n=5 mice). *, $p < 0.05$.